Guardant Health (GH) Proxy filing summary

Executive summary

• Achieved 33% year-over-year revenue growth in 2025, reaching $982 million, with 363,000 clinical tests delivered and strong momentum across Oncology, Screening, and Biopharma & Data segments.

• Oncology products saw record volume and revenue, with expanded Medicare coverage and new clinical evidence for Guardant Reveal, and the launch of Reveal Therapy Monitoring for late-stage cancer.

• Shield™ blood test for colorectal cancer screening completed its first full year post-FDA approval, generating $80 million in revenue and achieving ADLT status with a $1,495 Medicare reimbursement rate.

• Biopharma & Data business expanded to over 200 partners, with 25 regulatory clearances and notable collaborations, including AstraZeneca's SERENA-6 Phase III study.

• Real-world Shield performance remained strong, and a multi-cancer data collection initiative was launched.

Voting matters and shareholder proposals

• Election of two Class II directors (Ian Clark and Manuel Hidalgo Medina) for three-year terms.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory vote to approve named executive officer compensation (say-on-pay).

• Advisory vote on the frequency of future say-on-pay votes, with the Board recommending annual votes.

• No other shareholder proposals or nominations were received for this meeting.

Board of directors and corporate governance

• Board consists of 11 members, with 82% independence and 27% female representation; 36% are from underrepresented racial/ethnic groups.

• Board divided into three staggered classes; average director tenure is 5.2 years.

• Board committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent chairs.

• Lead Independent Director (Ian Clark) has defined responsibilities, including presiding over executive sessions.

• Annual self-evaluation and regular stockholder outreach are conducted.